5 completed, 2 unknown, 1 withdrawn. 8 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Unknown 2, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Contrast-induced Nephropathy: new trials by email Literature Review of Contrast-induced Nephropathy trials Research Report on Contrast-induced Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography CE-Iohexol, Iohexol - Contrast-induced Nephropathy | Phase 2 | Withdrawn | Ligand Pharmaceuticals | 2022-01-01 | 2022-04-11 | |
| Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI) Allopurinol, Febuxostat, Placebo - Contrast-induced Nephropathy, Contrast-induced Acute Kidney Injury | Phase 2 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 558 | 2018-12-05 | 2018-12-06 |
| The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy Potassium Nitrate, Potassium Chloride - Contrast-induced Nephropathy, Acute Kidney Injury | Phase 2 | Completed | Barts & The London NHS Trust | 640 | 2018-11-29 | 2022-12-16 |
| The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography Spironolactone, Placebo Oral Tablet - Acute Kidney Injury, IHD | Phase 2 | Completed | Alhasan Mujtaba Abdul-Wahid | 490 | 2017-09-01 | 2018-09-10 |
| Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy. Atorvastatin, Carvedilol, saline - Contrast-induced Nephropathy | Phase 2 | Completed | rabab ahmed mohamed | 144 | 2016-02-01 | 2019-03-12 |
| Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy N-acetylcysteine, Theophylline, 0.9% sodium chloride - Contrast-Induced Nephropathy | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 96 | 2013-09-01 | 2014-03-17 |
| High Dose Atorvastatin for Preventing Contrast-induced Nephropathy Atorvastatin, Placebo, 0.9% sodium chloride - Contrast-Induced Nephropathy | Phase 2 / Phase 3 | Completed | Isfahan University of Medical Sciences | 250 | 2013-07-01 | 2014-04-15 |
| Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction intravenous and oral N-acetylcysteine - Contrast-Induced Nephropathy, Acute Myocardial Infarction | Phase 2 / Phase 3 | Completed | University of Milan | 300 | 2003-02-01 | 2006-07-18 |
Acute Kidney Injury (2) · Acute Coronary Syndrome (1)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Renal Insufficiency (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Cardiovascular Diseases (1) · Heart Diseases (1) · Myocardial Ischemia (1) · Vascular Diseases (1)
Sodium Chloride (3) · Acetylcysteine (2) · Atorvastatin (2) · Allopurinol (1) · Carvedilol (1) · Control Groups (1) · Febuxostat (1) · Iohexol (1) · Potassium Chloride (1) · Spironolactone (1) · Theophylline (1) · potassium nitrate (1)
Isfahan University of Medical Sciences (2) · Alhasan Mujtaba Abdul-Wahid (1) · Barts & The London NHS Trust (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Ligand Pharmaceuticals (1) · University of Milan (1) · rabab ahmed mohamed (1)
Iran (2) · Iraq (1) · Italy (1) · Mexico (1) · United Kingdom (1)
Alhasan Mujtaba, BCPS (1) · Alireza Hajian, M.D. (1) · Amrita Ahluwalia, PhD (1) · Antonio L Bartorelli, MD (1) · Assad H Kata, Ph.D (1) · Hamid A Abdulsada, Ph.D (1) · Hassan M Al Rubaye, Ph.D (1) · Hayder K Abdullkreem, M.Sc (1) · Keith Marschke, PhD (1) · Magdalena Madero, MD (1) · Mazin A Hazzaa', Ph.D. (1) · Mohammed A Taher, Ph.D. (1) · Mortaza Arabmomeni, M.D. (1)